Macy’s (NYSE: M) reported second-quarter financial results before the opening bell on Wednesday. The department store chain reported a 36% decrease in Q2 revenues to $3.56 billion, beating Wall Street consensus. Adjusted loss per share of $0.81 per share was also narrower than what analysts had anticipated.
M shares rose 5% immediately following the announcement. The stock has declined 58% so far this year.
“We are encouraged by our second-quarter performance; however, we continue to approach the back half of the year conservatively. Our immediate priority is successfully executing Holiday 2020,” CEO Jeff Gennette said in a statement.
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key